PL3810626T3 - Związki antagonistyczne wobec pcsk9 - Google Patents

Związki antagonistyczne wobec pcsk9

Info

Publication number
PL3810626T3
PL3810626T3 PL19739801.9T PL19739801T PL3810626T3 PL 3810626 T3 PL3810626 T3 PL 3810626T3 PL 19739801 T PL19739801 T PL 19739801T PL 3810626 T3 PL3810626 T3 PL 3810626T3
Authority
PL
Poland
Prior art keywords
antagonist compounds
pcsk9 antagonist
pcsk9
compounds
antagonist
Prior art date
Application number
PL19739801.9T
Other languages
English (en)
Inventor
Harold B. Wood
Hubert B. Josien
Thomas Joseph Tucker
Angela Dawn Kerekes
Ling Tong
Abbas M. Walji
Anilkumar G. Nair
Fa-Xiang Ding
Elisabetta Bianchi
Danila Branca
Chengwei WU
Yusheng Xiong
Sookhee Nicole Ha
Jian Liu
Sobhana Babu Boga
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of PL3810626T3 publication Critical patent/PL3810626T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19739801.9T 2018-06-21 2019-06-20 Związki antagonistyczne wobec pcsk9 PL3810626T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21
PCT/US2019/038155 WO2019246349A1 (en) 2018-06-21 2019-06-20 Pcsk9 antagonist compounds

Publications (1)

Publication Number Publication Date
PL3810626T3 true PL3810626T3 (pl) 2025-12-22

Family

ID=67263083

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19739801.9T PL3810626T3 (pl) 2018-06-21 2019-06-20 Związki antagonistyczne wobec pcsk9

Country Status (38)

Country Link
US (3) US11427616B2 (pl)
EP (2) EP3810626B1 (pl)
JP (3) JP7112531B2 (pl)
KR (2) KR20250161677A (pl)
CN (2) CN121130044A (pl)
AR (1) AR115597A1 (pl)
AU (2) AU2019290163C1 (pl)
BR (1) BR112020025274A8 (pl)
CA (1) CA3102629A1 (pl)
CL (2) CL2020003257A1 (pl)
CO (1) CO2021000456A2 (pl)
CR (1) CR20210031A (pl)
DK (1) DK3810626T3 (pl)
DO (1) DOP2020000250A (pl)
EA (1) EA202190086A1 (pl)
EC (1) ECSP21003643A (pl)
ES (1) ES3047399T3 (pl)
FI (1) FI3810626T3 (pl)
GE (2) GEP20237506B (pl)
HR (1) HRP20251302T1 (pl)
HU (1) HUE073367T2 (pl)
IL (2) IL279363B2 (pl)
JO (1) JOP20190150A1 (pl)
LT (1) LT3810626T (pl)
MA (1) MA52967B1 (pl)
MD (1) MD3810626T2 (pl)
MX (1) MX2020013726A (pl)
NI (1) NI202000101A (pl)
PE (1) PE20211584A1 (pl)
PH (1) PH12020552187A1 (pl)
PL (1) PL3810626T3 (pl)
PT (1) PT3810626T (pl)
RS (1) RS67338B1 (pl)
SG (1) SG11202012451WA (pl)
SI (1) SI3810626T1 (pl)
TW (1) TWI840376B (pl)
UA (1) UA129467C2 (pl)
WO (1) WO2019246349A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
HRP20250769T1 (hr) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
WO2023023245A1 (en) * 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Compounds for treating conditions related to pcsk9 activity
CN119866342A (zh) 2022-06-15 2025-04-22 默沙东有限责任公司 用于捕获白介素-1β的环肽
JP2025527471A (ja) * 2022-08-17 2025-08-22 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｃｓｋ９阻害薬の結晶形態、組成物及び使用
WO2024259310A2 (en) * 2023-06-15 2024-12-19 Merck Sharp & Dohme Llc Passive permeable pcsk9 antagonist compounds
US20250152658A1 (en) 2023-11-14 2025-05-15 Merck Sharp & Dohme Llc Cyclic peptide for trapping interleukin-1 beta
TW202542176A (zh) 2023-12-15 2025-11-01 美商默沙東有限責任公司 用於治療動脈粥樣硬化及發炎病症之環狀肽IL-1β捕捉劑
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2025264781A1 (en) * 2024-06-18 2025-12-26 Kemira Oy J Cationizing agents for saccharides and methods
WO2026019622A1 (en) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Crystal forms of a cyclictetrapeptide and processes for preparing
WO2026032253A1 (zh) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 环肽类似物及其制备方法和用途
WO2026034639A1 (ja) * 2024-08-09 2026-02-12 株式会社Spin Wave ペプチド合成用可溶性担体およびこれを用いた合成方法
CN119930471A (zh) * 2024-12-31 2025-05-06 苏州默迪夫生物科技有限公司 Mk-a的制备方法、所用的中间体及其合成方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
US4656269A (en) 1986-04-15 1987-04-07 Kissei Pharmaceutical Co., Ltd. Histidine derivatives
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6054587A (en) 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
ATE246197T1 (de) 1998-09-09 2003-08-15 Metabasis Therapeutics Inc Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004019869A2 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
WO2004020408A1 (en) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles having anti-diabetic activity
JP2007504285A (ja) 2003-01-17 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体
CA2667894A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
AU2008267724A1 (en) 2007-06-28 2008-12-31 Merck Frosst Canada Ltd Substituted fused pyrimidines as antagonists of GPR105 activity
EP2174343A1 (en) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Manufacturing method of semiconductor device
WO2009042053A2 (en) 2007-09-21 2009-04-02 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009148605A2 (en) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
PH12013501393A1 (en) 2010-12-28 2013-08-28 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
AU2012214251A1 (en) * 2011-02-11 2013-09-12 Novartis Ag PCSK9 antagonists
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
EP2721063A4 (en) 2011-06-20 2015-01-14 Hoffmann La Roche PCSK9 BINDING POLYPEPTIDES AND METHOD OF USE THEREOF
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
EP2814501A4 (en) 2012-03-13 2016-03-02 Tensive Controls Inc MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
EP2850095B1 (en) 2012-05-17 2019-10-09 RA Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
EP2684865A1 (en) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
CN105228616B (zh) 2013-03-15 2019-05-03 实发生物医学公司 抗前蛋白转化酶枯草杆菌蛋白酶Kexin 9型（抗PCSK9）化合物及其用于治疗和/或预防心血管疾病的方法
KR20220048051A (ko) 2013-10-11 2022-04-19 사노피 바이오테크놀로지 고지혈증을 치료하기 위한 ｐｃｓｋ9 억제제의 용도
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
US10557129B2 (en) 2015-01-30 2020-02-11 Pronasci Inc. Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity
US10822385B2 (en) 2016-01-13 2020-11-03 Novo Nordisk A/S EGF(A) analogues with fatty acid substituents
CN107286158A (zh) 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
BR112018076242A2 (pt) 2016-06-24 2019-03-26 Hoffmann La Roche inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
EP3579152B1 (en) 2017-04-20 2022-09-14 Shanghai Cambricon Information Technology Co., Ltd Computing apparatus and related product
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
IL279363B2 (en) * 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
US11530244B2 (en) 2018-06-21 2022-12-20 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
ES3013570T3 (en) 2018-06-21 2025-04-14 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
EP3810178A4 (en) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. CYCLIC POLYPEPTIDES TO INHIBIT PCSK9
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds

Also Published As

Publication number Publication date
EP4660303A3 (en) 2026-02-25
US20250206781A1 (en) 2025-06-26
FI3810626T3 (fi) 2025-10-21
US20230159592A1 (en) 2023-05-25
LT3810626T (lt) 2025-11-10
EP3810626B1 (en) 2025-07-23
IL279363B2 (en) 2025-12-01
KR20250161677A (ko) 2025-11-17
JP7607615B2 (ja) 2024-12-27
EA202190086A1 (ru) 2021-05-18
IL279363A (en) 2021-01-31
HUE073367T2 (hu) 2026-01-28
AU2019290163C1 (en) 2022-11-03
CR20210031A (es) 2021-02-11
DOP2020000250A (es) 2021-02-28
PE20211584A1 (es) 2021-08-18
WO2019246349A1 (en) 2019-12-26
MA52967A (fr) 2021-04-28
DK3810626T3 (da) 2025-08-18
AR115597A1 (es) 2021-02-03
SI3810626T1 (sl) 2025-12-31
CL2020003257A1 (es) 2021-07-23
CL2022000027A1 (es) 2022-08-19
ES3047399T3 (en) 2025-12-03
GEAP202215540A (en) 2022-12-12
JP7112531B2 (ja) 2022-08-03
EP4660303A2 (en) 2025-12-10
RS67338B1 (sr) 2025-11-28
CN121130044A (zh) 2025-12-16
GEP20237506B (en) 2023-05-25
PH12020552187A1 (en) 2021-07-26
CA3102629A1 (en) 2019-12-26
MX2020013726A (es) 2021-03-02
EP3810626A1 (en) 2021-04-28
SG11202012451WA (en) 2021-01-28
JP2022141879A (ja) 2022-09-29
MA52967B1 (fr) 2025-09-30
CO2021000456A2 (es) 2021-01-29
WO2019246349A8 (en) 2021-02-04
TW202019950A (zh) 2020-06-01
HRP20251302T1 (hr) 2025-12-19
AU2019290163B2 (en) 2022-08-04
IL321719A (en) 2025-08-01
ECSP21003643A (es) 2021-02-26
TWI840376B (zh) 2024-05-01
KR102884527B1 (ko) 2025-11-13
BR112020025274A8 (pt) 2023-02-14
NI202000101A (es) 2021-05-28
UA129467C2 (uk) 2025-05-07
AU2019290163A1 (en) 2021-01-07
PT3810626T (pt) 2025-10-15
JP2025041712A (ja) 2025-03-26
CN112313243B (zh) 2025-09-02
KR20210024035A (ko) 2021-03-04
JP2021522311A (ja) 2021-08-30
BR112020025274A2 (pt) 2021-03-09
US12209145B2 (en) 2025-01-28
MD3810626T2 (ro) 2025-12-31
JOP20190150A1 (ar) 2019-12-21
AU2022259744B2 (en) 2024-07-11
IL279363B1 (en) 2025-08-01
US11427616B2 (en) 2022-08-30
AU2022259744A1 (en) 2022-12-01
CN112313243A (zh) 2021-02-02
US20190389909A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
IL279363A (en) PCSK9 antagonist compounds
GB201805174D0 (en) Compounds
GB201801355D0 (en) Compounds
IL277651A (en) OXR2 compounds
GB201807924D0 (en) Compounds
GB201808093D0 (en) Compounds
GB201817047D0 (en) H4 antagonist compounds
GB201811169D0 (en) New compounds
GB201810668D0 (en) New compounds
GB201809102D0 (en) Compounds
GB201810669D0 (en) New compounds
GB201803340D0 (en) Compounds
GB201801128D0 (en) Compounds
GB201801130D0 (en) Compounds
HK40047118A (en) Pcsk9 antagonist compounds
GB201812604D0 (en) Antagonist compounds
GB201910865D0 (en) Antagonist compounds
GB201904158D0 (en) Antagonist compounds
GB201910526D0 (en) Antagonist
GB201909500D0 (en) Antagonist
GB201817634D0 (en) New compounds
GB201813681D0 (en) New compounds
GB201808568D0 (en) Compounds
GB201808572D0 (en) Compounds
GB201808576D0 (en) Compounds